Loading…
Atrium Therapeutics, Inc. is projected to rise to $13.64 by 2027, a +5% move from its current price of $13.00. RNA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $12.75 | $13.00 | $13.25 | -0.01% |
| May 30 | $12.65 | $13.00 | $13.35 | -0.02% |
| May 31 | $12.58 | $13.00 | $13.43 | -0.03% |
| Jun 1 | $12.51 | $12.99 | $13.50 | -0.04% |
| Jun 2 | $12.45 | $12.99 | $13.56 | -0.06% |
| Jun 3 | $12.40 | $12.99 | $13.61 | -0.07% |
| Jun 4 | $12.35 | $12.99 | $13.66 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.35 | $12.99 | $13.66 | -0.08% |
| Week 2 | $12.09 | $12.98 | $13.94 | -0.16% |
| Week 3 | $11.89 | $12.97 | $14.15 | -0.23% |
| Week 4 | $11.72 | $12.96 | $14.33 | -0.31% |
| Week 5 | $11.57 | $12.95 | $14.49 | -0.39% |
| Week 6 | $11.44 | $12.94 | $14.63 | -0.47% |
| Week 7 | $11.32 | $12.93 | $14.77 | -0.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Atrium Therapeutics, Inc. is a biopharmaceutical company focused on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. Its development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Atrium Therapeutics, Inc. (RNA) is a biopharmaceutical company focused on RNA therapeutics for heart conditions. The current price is $13.09 and the market cap is $223.91M. The stock ranks 3773 in market capitalization terms.
A major floor 12.5% below — a decisive break under it would weaken the trend.
The nearest floor, 3.5% below — buyers have tended to step in here.
The nearest ceiling, 11.8% above — a clean break opens room to run.
A major ceiling 27.2% above — clearing it would confirm fresh momentum.
Key RNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.98 | Buy | $13.02 | Sell |
| MA 10 | $13.06 | Sell | $13.04 | Sell |
| MA 20 | $13.05 | Sell | $13.12 | Sell |
| MA 50 | $13.30 | Sell | $13.43 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.36 | Neutral |
| Stoch RSI (14) | 62.22 | Neutral |
| CCI (20) | -26.23 | Neutral |
| Williams %R (14) | -51.72 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -0.54 | Sell |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 48.28 | Neutral |
| TRIX (15) | -0.16 | Sell |
| Awesome (5,34) | -0.32 | Sell |
| Ultimate (7,14,28) | 41.39 | Neutral |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | -12.00 | Sell |
| Hull MA (9) | 13.04 | Sell |
| ADX (14) | 8.57 | Neutral |
| ATR (14) | 0.21 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 50. The 50-day simple moving average is $13.33, providing a nearby benchmark for price action.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.32 | $13.00 | $16.13 | 0% | Neutral | |
| $10.77 | $13.64 | $18.32 | +5% | Neutral | |
| $11.73 | $15.27 | $21.29 | +17% | Neutral | |
| $13.55 | $18.08 | $25.95 | +39% | Bullish | |
| $13.61 | $18.55 | $27.29 | +43% | Bullish | |
| $13.26 | $18.43 | $27.70 | +42% | Bullish | |
| $14.37 | $20.32 | $31.15 | +56% | Bullish | |
| $14.06 | $20.23 | $31.57 | +56% | Bullish | |
| $15.35 | $22.45 | $35.59 | +73% | Bullish | |
| $18.29 | $27.16 | $43.72 | +109% | Bullish | |
| $21.79 | $34.72 | $59.53 | +167% | Bullish | |
| $32.32 | $58.21 | $109.42 | +348% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $12.32 | $13.00 | $15.29 | +0.00% |
| June 2026 | $11.00 | $12.93 | $15.56 | -0.57% |
| July 2026 | $10.85 | $12.87 | $15.71 | -0.44% |
| August 2026 | $11.01 | $13.15 | $16.23 | +2.17% |
| September 2026 | $10.89 | $13.08 | $16.29 | -0.52% |
| October 2026 | $10.45 | $12.62 | $15.83 | -3.55% |
| November 2026 | $10.33 | $12.53 | $15.83 | -0.71% |
| December 2026 | $10.41 | $12.68 | $16.13 | +1.23% |
Click any year to see its month-by-month RNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RNA could reach as high as $16.13, with a base case around $13.00 and support toward $12.32 — roughly 0% from $13.00. Price action looks broadly range-bound.
Expect RNA to range from $10.77 to $18.32 through 2027. The $13.64 average target implies a +5% move from current prices. That is up +5% on the projected 2026 average. A consolidation phase looks the most probable path here.
The RNA price prediction for 2028 points to an average of $15.27 (low $11.73, high $21.29) — a potential gain of +17% on today's $13.00. Price action looks broadly range-bound.
In 2029, RNA is projected to trade between $13.55 and $25.95, averaging $18.08 — a potential gain of +39% from today's $13.00. That is up +18% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Atrium Therapeutics, Inc.'s 2030 outlook centres on $18.55, within a $13.61 to $27.29 range. That is up +3% on the projected 2029 average. That marks a +43% change versus current levels. Momentum favours further upside here.
By 2031, RNA could reach as high as $27.70, with a base case around $18.43 and support toward $13.26 — roughly +42% from $13.00. Buyers look set to stay in control over this stretch.
Expect RNA to range from $14.37 to $31.15 through 2032. The $20.32 average target implies a +56% move from current prices. That is up +10% on the projected 2031 average. Momentum favours further upside here.
The RNA price prediction for 2033 points to an average of $20.23 (low $14.06, high $31.57) — a potential gain of +56% on today's $13.00. Buyers look set to stay in control over this stretch.
In 2034, RNA is projected to trade between $15.35 and $35.59, averaging $22.45 — a potential gain of +73% from today's $13.00. That is up +11% on the projected 2033 average. Momentum favours further upside here.
Atrium Therapeutics, Inc.'s 2035 outlook centres on $27.16, within a $18.29 to $43.72 range. That is up +21% on the projected 2034 average. That marks a +109% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RNA could reach as high as $59.53, with a base case around $34.72 and support toward $21.79 — roughly +167% from $13.00. Momentum favours further upside here.
Expect RNA to range from $32.32 to $109.42 through 2050. The $58.21 average target implies a +348% move from current prices. That is up +68% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RNA today (≈ 76.923077 RNA) could be worth
$4,477.93
+$3,477.93 (+348%) by 2050 · US Dollar
Based on the average projected RNA price of $58.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNAwould be worth at today's price.
$1,000 invested in RNA on Feb 27, 2026 (≈ 67.79661 RNA) would be worth
$881.36
-$118.64 (-11.9%) today · 0.88× · US Dollar
Based on a RNA entry price of $14.75 vs. today's $13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.72 | $1,022.01 | +2.2% |
| 1 month ago | $12.9 | $1,007.75 | +0.8% |
| 3 months ago | $14.75 | $881.36 | -11.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNA forecast.
Our base-case forecast reaches $26.00 around 2035.
Implied market cap at $26.00: $444.75M
The multi-year forecast shows a bullish path with rising average prices over time. The 2026 average is $13.09 with a max of $16.35 and a min of $12.32 (ROI 0). By 2027 the average is $13.74 (ROI 4.9%), and by 2028 the average is $15.52 (ROI 18.6%).
The trajectory turns more pronounced from 2029 onward, with 2029 average $18.23 (ROI 39.3%), 2030 average $18.67 (ROI 42.6%), 2031 average $18.71 (ROI 42.9%), 2032 average $20.53 (ROI 56.8%), 2033 average $20.39 (ROI 55.8%), 2034 average $22.82 (ROI 74.3%), and 2035 average $27.53 (ROI 110.3%). The path continues to 2040 with average $35.36 (ROI 170.1%) and to 2050 with average $58.85 (ROI 349.6%). Sentiment shifts from NEUTRAL in 2026–2028 to BULLISH from 2029 onward, reflecting an increasingly optimistic long-term view.
Tap a question to reveal the answer.
Avg $18.67, min $13.54, max $27.85, ROI 42.6%, sentiment BULLISH.
The forecast shows a bullish long-term path with higher averages and ROIs in later years (e.g., 2029 avg $18.23, ROI 39.3%; 2050 avg $58.85, ROI 349.6%), though 2026 is Neutral with ROI 0%.
Yes, the max forecast for 2050 is $113.34.
Current price $13.09; Market cap $223.91M.
30-day range low $11.46, high $14.95; Support $12.55; Resistance $14.54.
Atrium Therapeutics, Inc. Community Discussion
0Share your Atrium Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.